New urinary biomarkers show promise for bladder cancer detection and recurrence prediction. Learn more about this non-invasive diagnostic approach.

ImmunityBio has successfully closed a $100 million financing arrangement aimed at accelerating the worldwide commercial launch of its bladder cancer treatment, ANKTIVA®. The market responded ...

The U.S. Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

ImmunityBio stock sinks 21% after the FDA flags misleading claims on cancer drug Anktiva, citing exaggerated benefits and ...

BTIG maintained its 'Buy' rating and $13 price target, implying about 75% upside, and said the warning relates to promotion ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a ...

ImmunityBio (IBRX) stock plummeted 21% after the FDA issued a warning letter citing false advertising claims about its ...

ImmunityBio (IBRX) stock falls as the FDA issues a warning letter regarding a TV commercial and a podcast related to the ...

ImmunityBio (IBRX) drew investor attention after Macau regulators approved ANKTIVA for certain bladder cancer patients, and updated US NCCN guidelines widened the group of patients highlighted for ...